Original Article

An Evaluation of Inhaled Bronchodilator Therapy in Patients Hospitalized for Non-Life-Threatening COPD Exacerbations

Authors: J. Andrew Woods, PharmD, BCPS, Justin B. Usery, PharmD, BCPS, Timothy H. Self, PharmD, Christopher K. Finch, PharmD, BCPS

Abstract

Objective.: Chronic obstructive pulmonary disease (COPD) increasingly is a cause of morbidity and mortality in and economic burden on the US healthcare system, and COPD exacerbations continue to be among the top 10 causes of hospitalization in adults. The objective of this study was to evaluate the incidence and potential implications of missed scheduled nebulized bronchodilator therapy in the setting of acute, non-life-threatening COPD exacerbations.


Materials and Methods.: This study was a retrospective chart review of all of the patients with a primary diagnosis of severe, non-life-threatening COPD exacerbations admitted from January 2007 to June 2008 at a university-affiliated hospital. Each patient's inhaled bronchodilator treatment regimen, including potential for nebulization to metered-dose inhaler (MDI) with valved holding chamber (VHC) conversion, was assessed.


Results.: A total of 259 patients met inclusion criteria: 235 (90.7%) patients received inhaled bronchodilators by nebulization alone in the treatment of COPD exacerbations; 81.1% of these patients could have used MDI with VHC. Patients missed 24.3% of their scheduled, nebulized bronchodilator doses.


Conclusions.: Patient care can be improved through the initiation of MDI with VHC, especially considering the number of missed nebulizations that these patients experienced. Development of an inhaled bronchodilator treatment algorithm for COPD exacerbations should be considered to ensure an evidence-bassed medicine approach to these patients.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. National Heart Lung and Blood Institute factbook: disease statistics. 2007. Available at: http://www.nhlbi.nih.gov/about/factbook/chapter4.htm. Accessed May 2, 2011.
 
2. Agency for Healthcare Research and Quality. HCUPnet: healthcare cost and utilization project. Available at: http://hcupnet.ahrq.gov/. Accessed May 2, 2011.
 
3. World Health Organization. Chronic Respiratory Diseases. Chronic obstructive pulmonary disease. Available at: http://www.who.int/respiratory/copd/en/. Accessed August 28, 2008.
 
4. Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) executive summary. Am J Respir Crit Care Med. 2007;176:532-555.
 
5. Lindenauer PK, Pekow P, Gao S, et al. Quality of care for patients hospitalized for acute exacerbations of chronic obstructive pulmonary disease. Ann Intern Med. 2006;144:894-903.
 
6. Bowton DL, Goldsmith WM, Haponik EF. Substitution of metered-dose inhalers for hand-held nebulizers: success and cost savings in a large acute-care hospital. Chest. 1992;101:305-308.
 
7. Summer W, Elston R, Tharpe L, et al. Aerosol bronchodilator delivery methods: relative impact on pulmonary function and cost of respiratory care. Arch Intern Med. 1989;149:618-623.
 
8. Turner MO, Gafni A, Swan D, FitzGerald M. A review and economic evaluation of bronchodilator delivery methods in hospitalized patients. Arch Intern Med. 1996;156:2113-2118.
 
9. Dolovich MB, Ahrens RC, Hess DR, et al. Device selection and outcomes of aerosol therapy: evidence-based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology. Chest. 2005;127(1):335-371.
 
10. Tenholder MF, Bryson MJ, Whitlock WL. A model for conversion from small volume nebulizer to metered dose inhaler aerosol therapy. Chest. 1992;101:634-637.
 
11. Berry RB, Shinto RA, Wong FH, et al. Nebulizer vs. spacer for bronchodilator delivery in patients hospitalized for acute exacerbations of COPD. Chest. 1989;96:1241-1246.
 
12. Jasper AC, Mohsenifar Z, Kahan S, et al. Cost-benefit comparison of aerosol bronchodilator delivery methods in hospitalized patients. Chest. 1987;91:614-618.
 
13. Salyer JW, DiBlasi RM, Crotwell DN, et al. The conversion to metered-dose inhaler with valved holding chamber to administer inhaled albuterol: a pediatric hospital experience. Respir Care. 2008;53:338-345.
 
14. Mason N, Roberts N, Yard N, et al. Nebulisers or spacers for the administration of bronchodilators to those with asthma attending emergency departments? Respir Med. 2008;102:993-998.